Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
REGULATORY Government’s Pharma Innovation Panel to Propose Comprehensive Upgrades in Industry Policies
May 17, 2024
-
REGULATORY Japan to Simplify Keytruda’s Optimal Use Guidelines for 4 Indications
May 17, 2024
-
BUSINESS Mitsubishi Tanabe’s Earnings Sink 2-Digits in FY2023 on Backlash from Previous Gilenya Royalties
May 17, 2024
-
BUSINESS Eisai to Appoint CEO’s Son for Representative Post in Prelude to Succession
May 17, 2024
-
REGULATORY IBD Drugs Entyvio, Omvoh to Be Available for Self-Injection
May 17, 2024
-
BUSINESS Ultragenyx’s Evkeeza Gets Label Update to Allow Use under Age 5
May 17, 2024
-
BUSINESS No Clenafin Generic Competition until June 2025: Kaken
May 17, 2024
-
BUSINESS Japan Generic Market Set to Surpass 1.6 Trillion Yen by 2032: Fuji Keizai
May 17, 2024
-
BUSINESS Xocova Forerunner in March GP Rep Promotion Rankings: Intage
May 17, 2024
-
BUSINESS Eisai Begins Rolling Submission for Subcutaneous Leqembi in US
May 16, 2024
-
BUSINESS Eisai Sees Global Sales of Leqembi Surging to 56.5 Billion Yen in FY2024
May 16, 2024
-
REGULATORY First Innovation Premium in 6 Years Axed for Sargmalin, “Zero” Rule Hits Yet Again
May 16, 2024
-
REGULATORY Chuikyo OKs Listing of 18 Meds, All Get Price Premiums; Biggest Peak Sales for Beyfortus
May 16, 2024
-
REGULATORY Japan to Increase Reimbursement Rounds to 7 Times a Year from 2025
May 16, 2024
-
REGULATORY Alexion Takes Hit from 1st Market Expansion Re-Pricing of Ultomiris, Soliris
May 16, 2024
-
BUSINESS Mounjaro Going Back to Normal Supply from June: Lilly/Mitsubishi
May 16, 2024
-
BUSINESS Amgen Files BiTE Drug Tarlatamab for Lung Cancer in Japan
May 16, 2024
-
REGULATORY BMS’s Sotyktu to Get 8.6% Price Cut in August after Cost-Effectiveness Assessment
May 16, 2024
-
REGULATORY Annual Price Revisions Should Continue in 2025 and Beyond: MOF Budget Examiner
May 15, 2024
-
BUSINESS As Latuda Sales Evaporate, Sumitomo Shakes Up Top Brass for Turnaround
May 15, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…